Publications by authors named "Blake Max"

Claim this Profile
T
Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report.
Noora Kazanji, Blake Max, Rodrigo M Burgos, Jennifer T Pham, Catherine E Ford

Open Forum Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic.
Casey Morgan Luc, Blake Max, Sarah Pérez, Kara Herrera, Gregory Huhn

J Acquir Immune Defic Syndr· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time series DNA barcoding provides insight into factors influencing wood-boring and bark-feeding insect communities in Scots pine, Sitka spruce, and Noble fir stands.
Sophie de Becquevort, Niall J Mckeown, Max Blake, Paul W Shaw

Environ Entomol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Blake Max, Patricia DeMarais

Int J STD AIDS· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir.
Alex E Rock, Patricia L DeMarais, Pamala T Vergara-Rodriguez, Blake E Max

Infect Dis Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios.
Emily Huesgen, Kathryn E DeSear, Eric F Egelund, Renata Smith, Blake Max

Pharmacotherapy· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.
Francine Touzard Romo, Mariam Aziz, Britt Livak, Emily Huesgen, Ben Colton, Blake Max

J AIDS Clin Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide-associated thrombosis in the treatment of HIV-associated severe aphthous disease: a case report and review of the literature.
Aimee C Hodowanec, Alice Han, David E Barker, Paul G Rubinstein, Blake Max

J Int Assoc Physicians AIDS Care (Chic)· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.
Emily Huesgen, Rodrigo Burgos, Debra A Goldstein, Blake Max, Olamide D Jarrett

Antivir Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.
Gregory D Huhn, Sheila Badri, Sonia Vibhakar, Frank Tverdek, Christopher Crank, Blake Max

AIDS Res Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus?
Oluwatoyin Adeyemi, Sonia Vibhakar, Blake Max

Clin Infect Dis· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability at the lower limits of HIV-1 RNA quantification in clinical samples: a comparison of RT-PCR versus bDNA assays.
Ronald J Lubelchek, Blake Max, Caroline J Sandusky, Bala Hota, David E Barker

PLoS One· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
Sheila M Badri, Oluwatoyin M Adeyemi, Blake E Max, Bala N Hota, David E Barker

AIDS Patient Care STDS· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to 'limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis'.
Sheila M Badri, Oluwatoyin M Adeyemi, Blake E Max, David E Barker

AIDS· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of resistance testing ordering guidelines on rates of wild-type virus detection among patients for whom highly active antiretroviral therapy fails.
Toyin M Adeyemi, Blake Max, Sheila M Badri, David E Baker

J Acquir Immune Defic Syndr· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How does expert advice impact genotypic resistance testing in clinical practice?
Sheila M Badri, Oluwatoyin M Adeyemi, Blake E Max, Brandon M Zagorski, David E Barker

Clin Infect Dis· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing unit dose system discrepancies.
Blake E Max, Gail Itokazu, Larry H Danziger, Robert A Weinstein

Am J Health Syst Pharm· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis